Corcept Therapeutics | CORT - Gross Profit On Sales


Corcept Therapeutics reported $252.09M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
ANI Pharmaceuticals USD 143.88M 19.7M Mar/2026
Ardelyx USD 89.66M 24.7M Mar/2026
Aurora Cannabis CAD 29.79M 16.83M Mar/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Canopy Growth CAD 8.26M 13.2M Mar/2026
Corcept Therapeutics USD 252.09M 90.07M Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
J&J USD 18.55B 1.31B Jun/2026
Knight Therapeutics CAD 64.72M 8.91M Dec/2025
Lexicon Pharmaceuticals USD 5.29M 8.88M Dec/2025
Merck USD 12.09B 1.24B Mar/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Novartis USD 10.07B 758M Mar/2026
Omeros USD -33.16M 18.52M Jun/2024
Pacira USD 133.91M 7.27M Jun/2026
Pfizer USD -248M 11.29B Jun/2026
Supernus Pharmaceuticals USD 160.06M 30.7M Jun/2026
TG Therapeutics USD 199.14M 27.73M Jun/2026